Two cases of unresectable hepatocellular carcinoma treated via atezolizumab and bevacizumab combination therapy

BACKGROUND: Treatment of hepatocellular carcinoma (HCC) varies widely depending on the patient's condition. In recent years, combination therapy with immune checkpoint inhibitors has emerged as the treatment of choice due to its superior antitumor effects for unresectable HCC (uHCC). Conversion...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsunemitsu, Ryosuke, Tabuchi, Motoyasu, Sakamoto, Shinya, Ogi, Kenta, Matsumoto, Manabu, Iwata, Jun, Okabayashi, Takehiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236104/
https://www.ncbi.nlm.nih.gov/pubmed/37266831
http://dx.doi.org/10.1186/s40792-023-01678-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236104/
https://www.ncbi.nlm.nih.gov/pubmed/37266831
http://dx.doi.org/10.1186/s40792-023-01678-9

Ejemplares similares